Legal & General Group PLC Halozyme Therapeutics, Inc. Transaction History

Legal & General Group PLC

  • $470 Billion
  • Q3 2024

A detailed history of Legal & General Group PLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 228,624 shares of HALO stock, worth $10.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
228,624
Previous 228,624 -0.0%
Holding current value
$10.4 Million
Previous $13.1 Million -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$51.3 - $64.42 $17,031 - $21,387
332 Added 0.15%
228,624 $13.1 Million
Q2 2024

Aug 14, 2024
BUY
$37.81 - $52.4 $383,166 - $531,021
10,134 Added 4.65%
228,292 $12 Million
Q1 2024

May 14, 2024
SELL
$33.68 - $41.95 $279,611 - $348,268
-8,302 Reduced 3.67%
218,158 $8.87 Million
Q4 2023

Feb 15, 2024
SELL
$33.32 - $42.1 $314,707 - $397,634
-9,445 Reduced 4.0%
226,460 $8.37 Million
Q3 2023

Nov 14, 2023
SELL
$36.46 - $44.03 $253,105 - $305,656
-6,942 Reduced 2.86%
235,905 $9.01 Million
Q2 2023

Aug 14, 2023
SELL
$30.28 - $38.74 $1.27 Million - $1.63 Million
-42,046 Reduced 14.76%
242,847 $8.76 Million
Q1 2023

May 15, 2023
BUY
$32.86 - $55.7 $1.53 Million - $2.6 Million
46,663 Added 19.59%
284,893 $10.9 Million
Q4 2022

Feb 14, 2023
BUY
$40.06 - $59.44 $10,856 - $16,108
271 Added 0.11%
238,230 $13.6 Million
Q3 2022

Nov 14, 2022
SELL
$38.53 - $51.78 $1.32 Million - $1.77 Million
-34,166 Reduced 12.56%
237,959 $9.41 Million
Q2 2022

Aug 22, 2022
SELL
$37.35 - $48.3 $733,217 - $948,177
-19,631 Reduced 6.73%
272,125 $12 Million
Q1 2022

May 16, 2022
SELL
$31.97 - $41.06 $114,996 - $147,692
-3,597 Reduced 1.22%
291,756 $11.6 Million
Q4 2021

Feb 14, 2022
BUY
$31.82 - $40.75 $18,646 - $23,879
586 Added 0.2%
295,353 $11.9 Million
Q3 2021

Nov 15, 2021
BUY
$38.47 - $46.42 $1.4 Million - $1.69 Million
36,469 Added 14.12%
294,767 $12 Million
Q2 2021

Aug 12, 2021
BUY
$38.84 - $51.31 $1.44 Million - $1.9 Million
37,004 Added 16.72%
258,298 $11.7 Million
Q1 2021

May 17, 2021
SELL
$39.51 - $51.45 $26,234 - $34,162
-664 Reduced 0.3%
221,294 $9.23 Million
Q4 2020

Feb 12, 2021
BUY
$25.81 - $43.62 $2.9 Million - $4.9 Million
112,389 Added 102.57%
221,958 $9.48 Million
Q3 2020

Nov 13, 2020
SELL
$25.74 - $29.63 $311,119 - $358,137
-12,087 Reduced 9.94%
109,569 $2.88 Million
Q2 2020

Aug 14, 2020
BUY
$16.25 - $26.81 $315,428 - $520,408
19,411 Added 18.98%
121,656 $3.26 Million
Q1 2020

May 14, 2020
SELL
$13.9 - $21.83 $160,920 - $252,725
-11,577 Reduced 10.17%
102,245 $1.84 Million
Q4 2019

Feb 13, 2020
BUY
$14.93 - $19.53 $331,416 - $433,526
22,198 Added 24.23%
113,822 $2.02 Million
Q3 2019

Nov 13, 2019
BUY
$15.2 - $17.69 $342,471 - $398,573
22,531 Added 32.61%
91,624 $1.42 Million
Q2 2019

Aug 14, 2019
BUY
$14.75 - $17.26 $208,742 - $244,263
14,152 Added 25.76%
69,093 $1.19 Million
Q1 2019

May 15, 2019
SELL
$13.94 - $17.58 $191,898 - $242,006
-13,766 Reduced 20.04%
54,941 $884,000
Q4 2018

Feb 15, 2019
BUY
$13.33 - $18.66 $182,967 - $256,127
13,726 Added 24.96%
68,707 $1.01 Million
Q3 2018

Nov 20, 2018
BUY
$16.68 - $18.41 $200,893 - $221,730
12,044 Added 28.05%
54,981 $999,000
Q2 2018

Aug 10, 2018
SELL
$16.87 - $20.3 $32,744 - $39,402
-1,941 Reduced 4.33%
42,937 $724,000
Q1 2018

May 17, 2018
SELL
$17.06 - $21.2 $245,851 - $305,513
-14,411 Reduced 24.31%
44,878 $879,000
Q4 2017

Feb 13, 2018
BUY
$16.75 - $20.8 $993,090 - $1.23 Million
59,289
59,289 $1.21 Million

Others Institutions Holding HALO

# of Institutions
542
Shares Held
125M
Call Options Held
294K
Put Options Held
180K
View Full List

About HALOZYME THERAPEUTICS, INC.

HALO Quotes by TradingView
  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $6.36B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email